|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-12-21
|
|
pubmed:abstractText |
Women with ovarian cancer who experience disease progression during or within 6 months of first-line treatment with platinum-based anticancer drugs are considered to have platinum-resistant tumors. These patients have an unfavorable prognosis, and they frequently seek complementary and alternative therapies (CAM). Historically, this represents an understudied and underreported component of ovarian cancer treatment.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
100
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
205-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16171852-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16171852-Carboplatin,
pubmed-meshheading:16171852-Complementary Therapies,
pubmed-meshheading:16171852-Deoxycytidine,
pubmed-meshheading:16171852-Doxorubicin,
pubmed-meshheading:16171852-Drug Resistance, Neoplasm,
pubmed-meshheading:16171852-Female,
pubmed-meshheading:16171852-Genistein,
pubmed-meshheading:16171852-Glucuronides,
pubmed-meshheading:16171852-Humans,
pubmed-meshheading:16171852-Isoflavones,
pubmed-meshheading:16171852-Middle Aged,
pubmed-meshheading:16171852-Ovarian Neoplasms,
pubmed-meshheading:16171852-Paclitaxel,
pubmed-meshheading:16171852-Soy Milk,
pubmed-meshheading:16171852-Topotecan
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
|
|
pubmed:affiliation |
Division of Medical Oncology, Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, MA 02114, USA.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, N.I.H., Extramural
|
